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The laminin receptor Integrin a6b1 anchors adult neural stem cells to the niche vasculature. In this issue of
Cell Stem Cell, Lathia et al. (2010) show that glioblastoma stem cells highly express integrin a6 and that their
interaction with laminin on endothelial cells directly regulates their tumorigenic capacity.Glioblastoma multiforme (GBM) is the
most frequent and malignant primary
brain tumor. Despite advances in radio-
therapy, chemotherapy and aggressive
surgical resection treatments, the prog-
nosis remains dismal. After diagnosis,
patients have a mean survival of 15
months and a 2 year survival rate of
 25%. New directions for development
of cancer therapies have emerged with
the idea that malignant tumors harbor
a small subpopulation of cells that are
responsible for tumor propagation and
that share common features with their
tissue stem cell counterparts. These fea-
tures refer to their ability to grow under
stem cell selective conditions, their multi-
lineage differentiation potential, and their
extensive self-renewal, as indicated by
their ability to form tumors after single
and serial transplantation. Targeting these
glioma stem cells (GSCs) thus has the
potential to reduce tumor relapse and im-
prove chances of finding a final cure.
The difficult task of targeting GSCs
starts with the identification of this sub-
population within the tumor bulk. Re-
search on specific GSC markers has
been guided by previously acknowledged
markers of their neuronal stem cell coun-
terparts (NSCs). This is how CD133 and
CD15 came to the forefront as markers
for GSCs. CD133+ or CD15+ cells iso-
lated from GBM tumors fulfill the GSC’s
criteria; however, expression of these
markers is not consistently found in every
malignant brain tumor. Moreover, in a
recent study, patient-derived CD133 neg-
ative cells gave rise to tumors in nude rats,
findings that suggest that CD133 expres-
sion is not uniquely informative for all GSC
populations (Wang et al., 2008). Thus,
identifying additional GSC markers is animportant goal in cancer stem cell re-
search. In this issue of Cell Stem Cell,
Lathia et al. (2010) now add integrin a6
to the battery of known GSC markers.
Looking at the overlap of CD133+ and in-
tegrin a6+ populations, the authors find
that integrin a6 expression enriches for
GSCs in tumors that lack CD133 expres-
sion and that combining CD133 and in-
tegrin a6 expression results in a higher
enrichment of GSCs than CD133 expres-
sion alone. In addition to advancing our
ability to identify GSCs, the findings also
point to the potential of targeting integrin
a6 for antiglioblastoma therapy.
Lathia and colleagues examined integ-
rin a6 expression in biopsy samples from
glioblastoma patients and found that in-
tegrin a6+ cells were localized in close
proximity to the tumor vasculature and
often coexpressed the stem cell markers
CD133 and nestin. The authors next found
that patient-derived GSCs propagated as
xenografts had elevated levels of integrin
a6 expression relative to bulk glioma cells
and that integrin a6 and CD133 express-
ing GSC populations largely overlapped
as determined with FACS analysis and
immunostaining of tumorspheres gener-
ated from GSCs. To investigate the tu-
morigenic potential of integrin a6+ cells
relative to CD133 expression, Lathia
et al. studied self-renewal ability of
FACS-sorted tumor populations that are
single positive for integrin a6 and CD133
and double positive for both markers.
Integrin a6+ cells exhibited a high pro-
liferation rate as well as a high tumor-
sphere-building capacity both in the
absence and presence of CD133 expres-
sion. Xenotransplantation of integrin a6+
cells in the brains of immunocompro-
mised mice resulted in a higher incidenceCell Stem Cof secondary tumor formation and a re-
duced survival than what was obtained
with Integrin a6 cells. Altogether, these
findings establish integrin a6 as a novel
GSC marker and also suggest that integ-
rin a6 expression can be useful for identi-
fying GSCS in tumors with low or little
CD133 expression.
To address the functional role of integ-
rin a6 expression in GSCs, the authors
reduced integrin a6 expression using
siRNA or a blocking antibody that abol-
ishes the laminin-integrin a6 interaction.
Interestingly, this not only reduced pro-
liferation and tumorsphere-building ca-
pacity of GSCs but also resulted in a
strong increase in cell death. Accordingly,
when GSCs expressing siRNA against
integrin a6 or GSCs treated with integrin
a6 blocking antibody were injected into
the brains of immunocompromised mice,
these mice survived significantly longer
than mice with an intact integrin a6-lami-
nin interaction. Consequently, blocking
integrin a6 signaling could be a promising
therapeutic strategy.
The present findings raise questions of
whether integrin a6 expression on GSCs
has functional implications for tumor be-
havior. Integrins regulate stem-cell adhe-
sion to the extracellular matrix (ECM).
ECM proteins contain binding sites for
cell-adhesion molecules and growth
factors, which make them the ideal plat-
form to establish stablemorphogen gradi-
ents and enable molecular cross talk
(Hynes, 2009). Laminin contains multiple
EGF-like domains, which might bind to
EGF receptors and enable their crosstalk
with integrin a6b1 (Panayotou et al.,
1989). The integrin a6-laminin interaction
was recently reported to play an impor-
tant role in the subventricular zone (SVZ)ell 6, May 7, 2010 ª2010 Elsevier Inc. 403
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Figure 1. The Stem Cell Niche
(A) The SVZ stem cell niche showing the location of stem cells (B-type cells) and transit amplifying cells
(C-type cells) in close proximity to the vessels, whereas the more differentiated neuroblast (A-type cells)
migrate away from vessels within the niche.
(B) The glioma stem cell niche showing glioma-stem cells in close contact to the tumor vessels and the
longer distance to the vessels of the more differentiated ‘‘tumor cells.’’
(C) Magnification of boxed area in (A) and (B) showing the laminin-integrin a6b1 interaction. Laminin within
the extracellular matrix binds to the vessels and to the integrin a6b1 on stem cells, thereby anchoring stem
cells to vessels within the niche.
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(Shen et al., 2008). This neurogenic zone
contains an extensive, superficial network
of vasculature that acts as a niche for
neural stem and progenitor cells (Mirza-
deh et al., 2008; Shen et al., 2008; Tava-
zoie et al., 2008). In these studies, the
SVZ stem cells (B-type cells), and their
progeny, the highly proliferative transit-
amplifying cells (TACs; C-type cells)
were reported to be in direct or close con-
tact to the vasculature and to express
integrin a6. In contrast, the more differen-
tiated neuroblasts (A-type cells) were
more distally located and downregulated
integrin a6 expression (Figure 1). The
SVZ niche vasculature is surrounded by
branched structures of extracellular ma-
trix rich in laminin, also known as frac-
tones. In the SVZ, blocking the laminin-
integrin a6b1 interaction caused stem
cells to lose contact and move away
from the vascular niche (Shen et al.,
2008), suggesting that the integrin a6-404 Cell Stem Cell 6, May 7, 2010 ª2010 Elslaminin interaction is functionally impor-
tant for maintaining niche integrity and
regulating exit from the niche.
In the present study, Lathia et al. iden-
tify integrin a6 as a hallmark of GSCs.
Integrin a6 is also expressed outside of
the nervous system by tissue stem cells
including epidermal and mammary stem
cells andwas identified as part of a ‘‘stem-
ness’’ signature common to embryonic
and hematopoietic stem cells (Fortunel
et al., 2003). The paradox behavior of
NSCs andGSCs toward the same instruc-
tive molecule probably highlights the
aberrant lineage relationship of GSCs.
Accordingly, whereas NSCs are regarded
as a relatively quiescent population,
Lathia et al. show that integrin a6-labeled
GSCs consistently expressed the mito-
tic marker phosphohistone-3. Similarly,
CD133 expression in human neural stem
cells, as well as in colon cancer and mela-
noma cells, correlated with an enrichment
of cells in G2-M phase of the cell cycleevier Inc.(Sun et al., 2009). Therefore, the observed
correlation between CD15, CD133, and
integrin a6 expression with malignancy
might indicate an increased presence of
cycling transient-amplifying cells within
the tumor stem cell compartment; how-
ever, whether these markers identify
dormant glioma stem cells remains un-
clear. Similarly, expression of CD133 in-
creases upon exposure to ischemic
conditions or with the onset of angiogen-
esis, suggesting that it might rather be a
marker of tumor progression than a GSC
marker (Griguer et al., 2008; Wang et al.,
2008). The presence of potential dormant
stem cells in the integrin a6 population
would explain the reported tumor forma-
tion ability of both integrin a6+ and integrin
a6 cells. Further comprehensive charac-
terization of the tumor stem cell compart-
ment, as the one reported in this issue,
shall clarify whether we are still missing
the dormant GSCs.REFERENCES
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